Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Gyre Therapeutics, Inc. GYRE

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
0.95
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — 5 4 — — —
Insider Ownership
76.50%

Capital & Financial Ratios

Market Cap
764.50
Revenue
116.42
Net Income
(25.67)
Free Cash Flow
(7.12)
Net Debt
(74.80)
Current Ratio
4.26
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
6.53
P/B ratio
5.33
Past 5Y EPS Growth
48.82%
This Y EPS Growth
(2,100.00%)
Next Y EPS Growth
41.25%
Next 5Y EPS Growth
21.64%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 0.00
—
2022 0.00
—
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 33.51 26.67 52.43 74.80
Receivables 16.45 24.78 31.31 28.02
Inventory 4.28 6.34 10.17 11.43
Other 1.05 1.44 1.49 —
57.22 64.79 102.37 122.07
2023 2024 2025 Q'26
Payables 0.36 0.11 0.12 1.24
ST’ Debt — — — —
Other 0.04 5.02 0.01 —
20.05 19.52 18.29 28.66
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 22.52 29.11 — —
—
’25 22.06 29.73 30.56 34.23
116.59
’24 27.17 25.23 25.49 27.87
105.76
’23 24.93 29.33 32.04 27.15
113.45
’22 0.79 — — 101.50
102.29
’21 1.47 1.13 2.30 2.44
7.34
’20 16.37 1.66 0.89 2.03
20.95
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 3.18 (16.73) — —
—
’25 (0.13) (7.47) 14.24 (5.62)
1.01
’24 2.88 (5.49) 1.73 (2.76)
(3.64)
’23 10.42 4.53 7.58 3.36
25.89
’22 (12.05) (12.29) (7.28) 42.30
10.68
’21 (24.36) (20.12) (21.60) (17.68)
(83.75)
’20 (4.79) (15.14) (13.01) (22.11)
(55.05)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 3.00 (18.01) — —
—
’25 (0.95) (7.81) 13.63 (5.75)
(0.88)
’24 2.70 (6.73) 1.03 (3.36)
(6.37)
’23 8.61 2.19 5.97 1.20
17.97
’22 (12.05) (11.85) (7.28) 36.85
5.68
’21 (24.36) (20.47) (22.09) (17.68)
(84.59)
’20 (4.81) (15.15) (13.20) (22.15)
(55.31)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.10) (0.12) — —
—
’25 0.00 0.00 0.03 (0.02)
0.02
’24 0.03 0.01 0.01 0.00
0.05
’23 0.15 (1.05) (0.60) —
(1.41)
’22 (6.90) 24.59 (2.40) (19.19)
(3.90)
’21 (11.84) (9.60) (11.99) (9.60)
(43.03)
’20 (4.20) (14.39) (10.94) (12.89)
(43.93)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 5.25 2.85 8.26 6.11 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.35 30.40 27.45 13.75 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 7 593 579 625 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.61 0.19 0.18 0.19 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ 102.29 113.45 105.76 116.59 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 95.31% 95.91% 96.33% 95.35% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.41 (76.96) 23.22 14.44 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.20% (67.84%) 21.95% 12.38% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.31 (85.48) 17.90 9.88 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.13 1.11 1.59 2.52 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.61 1.72 1.24 1.30 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.90) (1.41) 0.14 0.06 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.17 0.39 (0.04) 0.01 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.08) (0.12) (0.03) (0.02) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.09 0.27 (0.07) (0.01) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.14 1.19 1.16 1.59 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 63.59 65.83 85.10 89.35 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ — ‡‡‡ ‡‡‡ 0.00 0.00 86.43 141.20 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ 5.26 13.80 9.74 5.41 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ 7.79 112.28 10.46 10.59 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ 5.03 13.55 9.53 4.66 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ 94.52 85.54 (158.15) (614.65) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.68 25.89 (3.64) 1.01 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.00) (7.92) (2.73) (1.89) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.68 17.97 (6.37) (0.88) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.41 37.17 45.27 84.08 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.04 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (25.14) (33.51) (26.67) (52.42) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 72.22 78.47 98.40 142.28 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.28% (92.34%) 9.99% 3.45% — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 12.22% (93.45%) 14.08% 7.99% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.06% (215.71%) 21.51% 4.18% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Gyre Therapeutics (GYRE), a clinical-stage biotech targeting fibrosis and inflammatory diseases, trades at a compelling discount, with analyst targets implying 100-150% upside amid a pivotal revenue inflection from Hydronidone’s China approval. Revenue exploded 1,295% YoY to $102 million in 2022, fueling explosive scaling—headcount from 7 to 593 employees—and gross margins stabilizing near 96%. Projections show steady growth to $146 million by 2026, with 2024 delivering a swing to $18.8 million profit and positive EPS, echoing resilient biotechs like Innovent that pivoted from R&D burn to commercialization.

A fortress balance sheet—cash-rich with near-zero debt and $98 million equity—bolsters the case, despite share dilution tripling counts and insider selling by the President (~$496K in 2025). Valuation multiples have compressed attractively (PS at 9.7x, PB 10.5x), signaling undervaluation versus peers, though lumpiness persists: 2023 losses and FCF reversals highlight biotech volatility.

Analysts bet on etrasimod catalysts and Hydronidone dominance for multi-year compounding, akin to Gilead’s fibrosis playbook, but risks like trial failures, China policy shifts, and absent insider buys demand caution. At current levels, GYRE merits a watchlist for 2026 readouts—position small, patience key.

Read full commentary →

Gyre Therapeutics, Inc. (GYRE) Latest News

News by impact score

Fine-tune

7 Aug

3 , 7:00 AM
Gyre Therapeutics reported second quarter 2026 and year-to-date financial results along with a business update. Quarterly financial results and business updates deliver data that moderately shifts company valuation and investor views.

12 May

4 GlobeNewswire, 4:05 PM
Gyre Therapeutics announces China's NMPA acceptance of the New Drug Application for F351 (hydronidone) to treat liver fibrosis induced by chronic hepatitis B. NMPA acceptance of the NDA for F351 advances a key pipeline candidate toward potential approval in China, significantly impacting Gyre's growth and market position.

7 May

4 GlobeNewswire, 6:00 AM
Gyre Therapeutics, Inc. (GYRE) reported first quarter 2026 financial results and provided a business update. Quarterly earnings reports with business updates often drive significant shifts in investor sentiment and stock performance for biotech firms.

3 , 7:45 AM
Gyre Therapeutics, Inc. (GYRE) reported a Q1 net loss and revenue that fell short of analyst estimates. Q1 loss and revenue shortfall will moderately influence financial performance and investor sentiment.

4 May

4 GlobeNewswire, 8:47 AM
Gyre Therapeutics, Inc. (GYRE) completed its acquisition of Cullgen, forming a fully integrated biopharmaceutical company with operations in the U.S. and China. The acquisition completion creates a fully integrated U.S.-China biopharma, significantly expanding Gyre's capabilities, pipeline, and market presence.

17 Mar

4 GlobeNewswire, 7:00 AM
China’s NMPA grants priority review to Gyre Therapeutics' NDA for Hydronidone (F351) to treat chronic hepatitis B-induced liver fibrosis. Priority review accelerates NDA approval timeline for Hydronidone, a key asset targeting large Chinese liver fibrosis market.

12 Mar

3 Zacks, 7:10 AM
Gyre Therapeutics, Inc. (GYRE) Q4 earnings missed estimates. Q4 earnings miss affects financial performance and investor sentiment moderately without fundamentally altering long-term trajectory.

3 GlobeNewswire, 6:00 AM
Gyre Therapeutics, Inc. (GYRE) reported fourth quarter and full year 2025 financial results, alongside a business update. Quarterly and annual financial results with business update moderately influence financial performance and investor sentiment.

3 Mar

4 TipRanks, 8:23 AM
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction. $300M all-stock acquisition of Cullgen represents a major strategic expansion for Gyre Therapeutics.

2 Mar

4 GlobeNewswire, 8:00 AM
Gyre Therapeutics enters agreement to acquire Cullgen, gaining targeted protein degradation platform and pipeline. Acquiring Cullgen's targeted protein degradation platform adds transformative technology and pipeline assets to Gyre's portfolio.

11 Feb

4 , 6:38 AM
Gyre Therapeutics, Inc. (GYRE) is highlighted among high-growth tech stocks in the U.S. for February 2026, showcasing its potential in the biotechnology sector. The company is recognized for its innovative approaches and strong market positioning, which are expected to drive significant growth in the coming months. Analysts are optimistic about GYRE's future performance, citing advancements in its product pipeline and strategic partnerships that could enhance its competitive edge. Significant product innovations and strategic partnerships are expected to alter the company's trajectory and investor sentiment.

26 Jan

4 Simply Wall St., 12:33 PM
Gyre Therapeutics, Inc. (GYRE) is gaining attention for its innovative approaches in the biotech sector, focusing on developing therapies for underserved conditions. The company is positioned to capitalize on emerging market trends and investor interest, potentially leading to significant growth opportunities. Analysts highlight GYRE's unique product pipeline and strategic partnerships as key factors that could enhance its market presence and financial performance in the coming years. Strategic partnerships and a unique product pipeline are likely to significantly impact Gyre Therapeutics' future performance and market position.

13 Jan

4 Simply Wall St., 6:38 AM
Gyre Therapeutics, Inc. (GYRE) is highlighted as a high-growth tech stock to watch in January 2026, reflecting its potential in the market. The company is positioned to capitalize on emerging trends and innovations within the tech sector, attracting investor interest. Analysts suggest that GYRE's strategic initiatives and product developments could enhance its competitive edge and financial performance in the coming months. Strategic initiatives and product developments are expected to significantly influence Gyre Therapeutics' market position and investor sentiment.

5 Jan

4 GlobeNewswire, 7:00 AM
Gyre Therapeutics, Inc. has announced alignment with China's Center for Drug Evaluation (CDE) regarding a conditional approval pathway and priority review eligibility for its drug Hydronidone, following a pre-New Drug Application (NDA) meeting. This development is expected to expedite the regulatory process for Hydronidone in China, potentially enhancing its market entry and availability. The alignment with China's CDE on regulatory pathways is a significant strategic move that could greatly influence Gyre's market performance and investor sentiment.

26 Dec

4 Simply Wall St., 6:32 AM
Gyre Therapeutics, Inc. (GYRE) is highlighted as a promising investment opportunity in December 2025, showcasing its innovative approaches in the biotech sector. The company is noted for its potential to address unmet medical needs, particularly in neurodegenerative diseases. Analysts suggest that GYRE's unique product pipeline and strategic partnerships position it favorably within the competitive landscape. Market sentiment is shifting positively towards GYRE, driven by recent advancements and a growing interest in biotech investments. Investors are encouraged to consider GYRE as a potential 'undiscovered gem' in the current market. Gyre Therapeutics is poised for significant impact due to its innovative product pipeline and strategic partnerships in the biotech sector.

15 Dec

3 Simply Wall St., 12:39 PM
Gyre Therapeutics, Inc. (GYRE) is highlighted among US high growth tech stocks to watch, indicating its potential for significant growth and innovation in the tech sector. The company is positioned to capitalize on emerging trends and market demands, making it a noteworthy player in the industry. Gyre Therapeutics is expected to experience moderate influence on its performance due to its positioning in a competitive tech landscape.

14 Nov

4 Simply Wall St., 6:38 AM
Gyre Therapeutics, Inc. (GYRE) is highlighted as a promising player in the high-growth tech sector within the US market. The company is noted for its innovative approaches and potential for significant market impact. Analysts are optimistic about GYRE's future, citing its strategic initiatives and advancements in technology that could enhance its competitive positioning. The overall sentiment surrounding GYRE reflects a growing interest in tech stocks that are poised for rapid expansion. Gyre Therapeutics is expected to experience significant impact due to its strategic initiatives and advancements in technology.

3 Simply Wall St., 5:26 AM
Gyre Therapeutics, Inc. (NASDAQ: GYRE) is facing underlying issues that may impact its earnings. Concerns have been raised regarding the company's financial performance and operational strategies, suggesting potential challenges ahead. Investors are advised to closely monitor these developments as they could influence market sentiment and the company's future trajectory. Underlying issues may moderately affect Gyre's financial performance and competitive positioning.

11 Nov

4 Simply Wall St., 12:33 PM
Gyre Therapeutics, Inc. (GYRE) is highlighted as a promising investment opportunity in the US market for November 2025, showcasing its innovative approaches in the biotech sector. The company is positioned to capitalize on emerging trends and advancements in therapeutics, potentially leading to significant growth and market interest. Analysts suggest that GYRE's unique product pipeline and strategic initiatives could attract investor attention, making it a noteworthy contender among lesser-known stocks. Gyre Therapeutics is expected to make significant strategic moves and product launches that could alter its market trajectory.

10 Nov

3 Simply Wall St., 6:41 AM
Gyre Therapeutics, Inc. (NASDAQ:GYRE) reported a return on equity (ROE) of 8.6%, raising concerns among investors regarding its efficiency in generating profits from shareholders' equity. Analysts suggest that while this figure is not alarming, it is below the industry average, indicating potential areas for improvement. The company may need to enhance its operational efficiency and strategic initiatives to boost profitability and investor confidence. The ROE figure suggests moderate concerns about profitability that could influence investor sentiment and operational strategies.

7 Nov

4 Zacks, 7:10 AM
Gyre Therapeutics, Inc. (GYRE) reported Q3 earnings that exceeded analysts' expectations, showcasing strong financial performance and growth potential. The company highlighted advancements in its product pipeline and strategic initiatives aimed at enhancing market presence. Investors reacted positively to the news, reflecting increased confidence in GYRE's future prospects. Earnings surpassing estimates and advancements in the product pipeline indicate significant potential for future growth and market performance.

3 , 6:00 AM
Gyre Therapeutics, Inc. reported its financial results for the third quarter of 2025 and year-to-date, highlighting key metrics and developments in its business operations. The company provided updates on its ongoing projects and strategic initiatives aimed at enhancing its market position and financial performance. The financial results and business updates indicate a moderately noticeable influence on Gyre's future performance and market positioning.

17 Oct

4 Zacks, 5:29 AM
Gyre Therapeutics, Inc. (GYRE) has been identified as a strong sell stock due to concerns regarding its financial performance and market position. Analysts highlight potential risks that could adversely affect the company's future prospects, leading to a negative outlook for investors. The stock's recent performance has raised alarms, prompting recommendations to divest. Concerns about financial performance and market position indicate significant potential impacts on future trajectory and investor sentiment.

15 Oct

4 GlobeNewswireClinical Trials ArenaZacks, 7:00 AM
Gyre Therapeutics, Inc. has completed patient enrollment in its Phase 3 clinical trial for Pirfenidone capsules aimed at treating pneumoconiosis. This milestone marks a significant step in the development of the treatment, which targets a serious lung disease caused by inhaling harmful dust. The trial's completion is expected to provide critical data on the efficacy and safety of Pirfenidone in this patient population. Completion of patient enrollment in a Phase 3 trial is a significant step that could lead to regulatory approval and market introduction of a new treatment.

14 Oct

4 Simply Wall St., 7:38 AM
Gyre Therapeutics, Inc. (GYRE) is highlighted as a high-growth tech stock to monitor in October 2025, reflecting its potential in the biotechnology sector. The company is noted for its innovative approaches and strategic initiatives that could position it favorably in the competitive landscape. Investors are encouraged to keep an eye on GYRE as it navigates market dynamics and seeks to capitalize on growth opportunities. Significant strategic initiatives and market positioning could greatly influence Gyre Therapeutics' future performance.

4 GlobeNewswire, 7:00 AM
Gyre Therapeutics, Inc. announced that it will present results from a positive Phase 3 clinical trial evaluating Hydronidone for treating liver fibrosis in patients with chronic Hepatitis B at the upcoming AASLD—The Liver Meeting® 2025. This presentation highlights the potential of Hydronidone as a significant treatment option in this area. The positive Phase 3 trial results could significantly impact Gyre Therapeutics' market position and investor sentiment regarding its product pipeline.

30 Sep

4 Simply Wall St., 1:33 PM
Gyre Therapeutics, Inc. (GYRE) is highlighted as one of three undiscovered investment opportunities in the U.S. market. The company is positioned in a promising sector with potential for growth, driven by innovative approaches and strategic initiatives. Analysts suggest that GYRE's unique offerings could attract investor interest, leading to significant market performance improvements. The article emphasizes the importance of recognizing such undervalued companies before they gain broader attention. Gyre Therapeutics is poised for significant growth due to its innovative strategies and market positioning.

5 Sep

3 GlobeNewswireGlobeNewswireGlobeNewswireGlobeNewswire, 4:05 PM
Gyre Therapeutics, Inc. (GYRE) will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its ongoing commitment to advancing its therapeutic pipeline and engaging with investors. The conference serves as a platform for the company to showcase its innovations and strategic direction to a global audience of investors and industry stakeholders. Participation in a significant investment conference may enhance investor interest and visibility but is not expected to fundamentally change the company's trajectory.

22 Aug

3 , 7:00 AM
Gyre Therapeutics, Inc. has appointed Dan Weng, M.D., to its Board of Directors. Dr. Weng brings extensive experience in the biotechnology sector, having held leadership roles in various companies. His expertise is expected to enhance Gyre's strategic direction and support its mission in developing innovative therapies. The appointment of a seasoned professional to the board may positively influence the company's strategic direction and operational effectiveness.

18 Aug

3 Simply Wall St., 6:15 AM
Gyre Therapeutics, Inc. (NASDAQ:GYRE) is facing scrutiny over the quality of its reported profits, raising concerns among investors about the sustainability and reliability of its financial performance. Analysts suggest that discrepancies in profit quality could impact the company's credibility and future growth prospects, leading to potential volatility in its stock price. Concerns over profit quality may moderately influence investor sentiment and financial performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us